These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38353182)

  • 1. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons.
    Seguí IG; Mingot Castellano ME; Izquierdo CP; de la Rubia J
    Expert Rev Hematol; 2024; 17(1-3):9-25. PubMed ID: 38353182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining the standard of care in immune thrombotic thrombocytopenic purpura.
    Laurence J
    Clin Adv Hematol Oncol; 2024 Oct; 22(8):381-391. PubMed ID: 39356816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.
    le Besnerais M; Veyradier A; Benhamou Y; Coppo P
    Expert Opin Biol Ther; 2019 Nov; 19(11):1127-1134. PubMed ID: 31359806
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.
    Kühne L; Knöbl P; Eller K; Thaler J; Sperr WR; Gleixner K; Osterholt T; Kaufeld J; Menne J; Buxhofer-Ausch V; Mühlfeld A; Seelow E; Schreiber A; Todorova P; Cukoski S; Jabs WJ; Özcan F; Gäckler A; Schönfelder K; Seibert FS; Westhoff T; Schwenger V; Eichenauer DA; Völker LA; Brinkkoetter PT
    Blood; 2024 Oct; 144(14):1486-1495. PubMed ID: 38838300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod A; Veyradier A; Coppo P
    J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura.
    Völker LA; Kaufeld J; Balduin G; Merkel L; Kühne L; Eichenauer DA; Osterholt T; Hägele H; Kann M; Grundmann F; Kolbrink B; Schulte K; Gäckler A; Kribben A; Boss K; Potthoff SA; Rump LC; Schmidt T; Mühlfeld AS; Schulmann K; Hermann M; Gaedeke J; Sauerland K; Bramstedt J; Hinkel UP; Miesbach W; Bauer F; Westhoff TH; Bruck H; Buxhofer-Ausch V; Müller TJ; Wendt R; Harth A; Schreiber A; Seelow E; Tölle M; Gohlisch C; Bieringer M; Geuther G; Jabs WJ; Fischereder M; von Bergwelt-Baildon A; Schönermarck U; Knoebl P; Menne J; Brinkkoetter PT;
    J Thromb Haemost; 2023 Mar; 21(3):559-572. PubMed ID: 36696206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
    Tse B; Buchholz M; Pavenski K
    Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
    Poullin P; Bornet C; Veyradier A; Coppo P
    Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
    Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
    Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
    [No Abstract]   [Full Text] [Related]  

  • 10. Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura.
    Kühne L; Kaufeld J; Völker LA; Wendt R; Schönermarck U; Hägele H; Osterholt T; Eichenauer DA; Bieringer M; von Bergwelt-Baildon A; Fischereder M; Buxhofer-Ausch V; Menne J; Brinkkoetter PT; Knöbl P
    J Thromb Haemost; 2022 Apr; 20(4):951-960. PubMed ID: 35000278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy.
    Mingot-Castellano ME; García-Candel F; Martínez-Nieto J; García-Arroba J; de la Rubia-Comos J; Gómez-Seguí I; Paciello-Coronel ML; Valcárcel-Ferreiras D; Jiménez M; Cid J; Lozano M; García-Gala JM; Angós-Vazquez S; Vara-Pampliega M; Guerra-Domínguez L; Ávila-Idrobo LF; Oliva-Hernandez A; Zalba-Marcos S; Tallón-Ruiz I; Ortega-Sánchez S; Goterris-Viciedo R; Moreno-Jiménez G; Domínguez-Acosta L; Araiz-Ramírez M; Hernández-Mateos L; Flores-Ballesteros E; Del Río-Garma J; Pascual-Izquierdo C
    Blood; 2024 May; 143(18):1807-1815. PubMed ID: 38237147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
    J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura.
    Gómez-Seguí I; Pascual Izquierdo C; de la Rubia Comos J
    Expert Rev Hematol; 2021 Aug; 14(8):707-719. PubMed ID: 34275393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. True vs. false immune-mediated thrombotic thrombocytopenic purpura exacerbations: a clinical case in the caplacizumab era.
    Laganà A; Trisolini SM; Maglione R; Mahnaz SB; Imperatore S; Vitullo D; Capria S
    Blood Coagul Fibrinolysis; 2024 Jan; 35(1):37-42. PubMed ID: 37994623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?
    Coppo P; Joly BS;
    Br J Haematol; 2023 Aug; 202(4):725-727. PubMed ID: 37291806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.
    Bowyer A; Brown P; Hopkins B; Scully M; Shepherd F; Lowe A; Mensah P; Maclean R; Kitchen S; van Veen JJ
    Br J Haematol; 2022 May; 197(3):349-358. PubMed ID: 35262910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five years of caplacizumab - lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura.
    Völker LA; Brinkkoetter PT; Cataland SR; Masias C
    J Thromb Haemost; 2023 Oct; 21(10):2718-2725. PubMed ID: 37562668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and Costs in Patients with Immune Thrombotic Thrombocytopenic Purpura Receiving Front-Line Versus Delayed Caplacizumab: A US Hospital Database Study.
    Arnaud A; Schilsky S; Lucia J; Maia M; Laredo F; Marques AP; Okada H; Roberts AW
    Clin Appl Thromb Hemost; 2024; 30():10760296241241525. PubMed ID: 38523315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
    He J; Qi J; Han H; Xu X; Li X; Song X; Han Y
    Expert Rev Hematol; 2023 May; 16(5):377-385. PubMed ID: 37045600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caplacizumab as rescue therapy in refractory TTP involving neurologic features.
    Tran MH; Lee LX; Cao Y; Vu L; Pakbaz Z
    Transfus Apher Sci; 2023 Jun; 62(3):103656. PubMed ID: 36863912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.